论文部分内容阅读
10 0例慢性乙型肝炎用重组干扰素α Ⅰb治疗 ,每支 30 0万IU ,隔日肌注 ,连续五个月为疗程。对照组用重组干扰素α Ⅱb治疗 ,其剂量、用法及疗程与治疗组相同。结果治疗组与对照组比较 ,于疗程结束时 :HBeAg转阴率各为 47 0 %与 45 0 % ;HBV -DNA转阴率各为 5 3 0 %与 5 0 0 %。停药一年后随访时 :HBeAg持续转阴率各为 37 0 %与 36 0 % ;HBV -DNA持续转阴率各为 39 0 %与 37 0 %。二组间二项相比 ,无显著性差异 (P >0 0 5 )。说明赛若金与干扰能相比 ,具有疗效相仿 ,副反应低的优点。另对赛若金治疗血清肝纤维化指标的观察 ,于疗程结束时 ,其治前与治后比较HA各为 16 2 7± 6 8 5与 97 5± 43 3;Ⅳ c各为 79 8± 36 7与 5 6 5± 2 4 2。二项前后相比有显著差异 (P <0 0 5 ) ,提示赛若金有抗肝纤维化疗效。
One hundred and ten patients with chronic hepatitis B were treated with recombinant interferon alpha Ib. Each 30,000 IU was intramuscularly injected every other day for five consecutive months. Control group with recombinant interferon α Ⅱ b treatment, the dose, usage and treatment with the same treatment group. Results Compared with the control group, the rates of HBeAg negative conversion were 47 0% and 45 0% respectively at the end of the treatment course. The negative conversion rates of HBV DNA were 53 0% and 50 0% respectively. At one year follow-up after discontinuation of treatment, the sustained negative rates of HBeAg were 37 0% and 36 0% respectively; the persistent negative rates of HBV DNA were 39 0% and 37 0% respectively. There was no significant difference between the two groups (P> 0.05). If the race gold and interference can be compared with the same effect, the advantages of low side effects. The other pairs of gold if the treatment of serum markers of liver fibrosis, at the end of the course of treatment, compared with pre-treatment and post-treatment HA were 16 2 7 ± 6 8 5 and 97 5 ± 43 3; IV c each for 79 8 ± 36 7 and 5 6 5 ± 2 4 2. There were significant differences (P <0.05) before and after the two items, suggesting that Saejin had anti-liver fibrosis effect.